Skip to main content

Why do Corals Glow?

For centuries, nature lovers and scientists have been fascinated by the fact that creatures in the sea are able to glow. The phenomenon is very common in reef-building corals, but its biological role has been the subject of constant debate. Numerous hypotheses have been tested over the years. Some suggested that this phenomenon protect against radiation. Or perhaps it contributed to the optimization of the photosynthesis? Maybe the glowing property helped protect the coral against herbivores or to attract symbiotic algae to the corals?

 

A new Tel Aviv University study, in collaboration with the Steinhardt Museum of Natural History, and the Interuniversity Institute for Marine Sciences in Eilat, has proven for the first time that the magical phenomenon – whereby corals in deep reefs display glowing colors (fluorescence) – is intended to serve as a mechanism for attracting prey.

 

The study was led by Dr. Or Ben-Zvi, in collaboration with Yoav Lindemann and Dr. Gal Eyal, under the supervision of Prof. Yossi Loya from the School of Zoology and the Steinhardt Museum of Natural History at Tel Aviv University.

 

Chasing the Glow

The researchers first sought to determine whether plankton (small organisms that drift in the sea along with the current) are attracted to fluorescence, both in the laboratory and at sea. Then, in the lab, the researchers quantified the predatory capabilities of mesophotic corals (corals that live between the shallow coral reef area and the deep, completely dark zone of ​​the ocean), which exhibit different fluorescent appearances.

 

To test the planktons’ potential attraction to fluorescence, the researchers used, among other things, the crustacean Artemia salina, which is used in many experiments as well as for food for corals. The researchers noted that when the crustaceans were given a choice between a green or orange, fluorescent target versus a clear ‘control’ target, they showed a significant preference for the fluorescent target.

 

Moreover, when the crustaceans were given a choice between two clear targets, its choices were observed to be randomly distributed in the experimental setup. In all of the laboratory experiments, the crustaceans vastly exhibited a preferred attraction toward a fluorescent signal. Similar results were presented when using a native crustacean from the Red Sea. However, unlike the crustaceans, fish that are not considered coral prey did not exhibit these trends, and rather avoided the fluorescent targets.

 

 

Fluorescent Traps

The second phase of the study was carried out about 40 meters deep in the sea, where the fluorescent traps (both green and orange) attracted twice as many plankton as the clear trap.

 

“We conducted an experiment in the depths of the sea to examine the possible attraction of diverse and natural collections of plankton to fluorescence, under the natural currents and light conditions that exist in deep water,” says Dr. Or Ben-Zvi. “Since fluorescence is ‘activated’ principally by blue light (the light of the depths of the sea), at these depths the fluorescence is naturally illuminated, and the data that emerged from the experiment were unequivocal, similar to the laboratory experiment.”

 

“This phenomenon may play a greater role in marine ecosystems than previously thought.”

 

 

The “Light Trap Hypothesis”

In the last part of the study, the researchers examined the predation rates of mesophotic corals that were collected at 45 m depth in the Gulf of Eilat. They found that corals that displayed green fluorescence enjoyed predation rates that were 25 percent higher than corals exhibiting yellow fluorescence.

 

Prof. Loya: “Many corals display a fluorescent color pattern that highlights their mouths or tentacle tips, a fact that supports the idea that fluorescence, like bioluminescence (the production of light by a chemical reaction), acts as a mechanism to attract prey. The study proves that the glowing and colorful appearance of corals can act as a lure to attract swimming plankton to ground-dwelling predators, such as corals, and especially in habitats where corals require other energy sources in addition or as a substitute for photosynthesis (sugar production by symbiotic algae inside the coral tissue using light energy).”

 

Dr. Ben-Zvi concludes: “Despite the gaps in the existing knowledge regarding the visual perception of fluorescence signals by plankton, the current study presents experimental evidence for the prey-luring role of fluorescence in corals. We suggest that this hypothesis, which we term the ‘light trap hypothesis’, may also apply to other fluorescent organisms in the sea, and that this phenomenon may play a greater role in marine ecosystems than previously thought.”

CRISPR Therapeutics can Damage the Genome

TAU Researchers caution that while the genome editing method is very effective, it is not always safe and can promote cancer.

A new study from TAU identifies risks in the use of CRISPR therapeutics – an innovative, Nobel-prize-winning method that involves cleaving and editing DNA, already employed for the treatment of conditions like cancer, liver and intestinal diseases, and genetic syndromes.

Investigating the impact of this technology on T-cells (white blood cells of the immune system), the researchers detected a loss of genetic material in a significant percentage – up to 10% of the treated cells. They explain that such loss can lead to destabilization of the genome, which might cause cancer.

The study was led by Dr. Adi Barzel from the School of Neurobiology, Biochemistry and Biophysics at TAU’s George S. Wise Faculty of Life Sciences and Dotan Center for Advanced Therapies, a collaboration between the Tel Aviv Sourasky Medical Center (Ichilov) and Tel Aviv University, and by Dr. Asaf Madi and Dr. Uri Ben-David from TAU’s Sackler Faculty of Medicine and Edmond J. Safra Center for Bioinformatics. The findings were published in the leading scientific journal Nature Biotechnology.

Cleavage Risk

The researchers explain that CRISPR is a groundbreaking technology for editing DNA – cleaving DNA sequences at certain locations to delete unwanted segments, or alternately repair or insert beneficial segments. Developed about a decade ago, the technology has already proved impressively effective in treating a range of diseases – cancer, liver diseases, genetic syndromes, and more.

The first approved clinical trial ever to use CRISPR, was conducted in 2020 at the University of Pennsylvania, when researchers applied the method to T-cells – white blood cells of the immune system. Taking T-cells from a donor, they expressed an engineered receptor targeting cancer cells, while using CRISPR to destroy genes coding for the original receptor – which otherwise might have caused the T-cells to attack cells in the recipient’s body.  

 

“CRISPR therapeutics, in which DNA is cleaved intentionally as a means for treating cancer, might, in extreme scenarios, actually promote malignancies.”

 

In the present study, the researchers sought to examine whether the potential benefits of CRISPR therapeutics might be offset by risks resulting from the cleavage itself, assuming that broken DNA is not always able to recover.

Dr. Ben-David and his research associate Eli Reuveni explain, “The genome in our cells often breaks due to natural causes, but usually it is able to repair itself, with no harm done. Still, sometimes a certain chromosome is unable to bounce back, and large sections, or even the entire chromosome, are lost. Such chromosomal disruptions can destabilize the genome, and we often see this in cancer cells. Thus, CRISPR therapeutics, in which DNA is cleaved intentionally as a means for treating cancer, might, in extreme scenarios, actually promote malignancies.”

To examine the extent of potential damage, the researchers repeated mentioned 2020 Pennsylvania experiment, cleaving the T-cells’ genome in the same locations – chromosomes 2, 7, and 14 (of the human genome’s 23 pairs of chromosomes). Using a state-of-the-art technology called ‘single-cell RNA sequencing’ they analyzed each cell separately and measured the expression levels of each chromosome in every cell.

Significant Loss of Genetic Material

A significant loss of genetic material was detected in some of the cells. For example, when Chromosome 14 had been cleaved, about 5% of the cells showed little or no expression of this chromosome. When all chromosomes were cleaved simultaneously, the damage increased, with 9%, 10%, and 3% of the cells unable to repair the break in chromosomes 14, 7, and 2 respectively. The three chromosomes did differ, however, in the extent of the damage they sustained. 

“Single-cell RNA sequencing and computational analyses enabled us to obtain very precise results,” explain Dr. Madi and his student Ella Goldschmidt, adding: “We found that the cause for the difference in damage was the exact place of the cleaving on each of the three chromosomes. Altogether, our findings indicate that over 9% of the T-cells genetically edited with the CRISPR technique had lost a significant amount of genetic material. Such loss can lead to destabilization of the genome, which might promote cancer.”

 

“We advance this highly effective technology, while at the same time cautioning against its potential dangers. This may seem like a contradiction, but as scientists we are quite proud of our approach, because we believe that this is the very essence of science: we don’t ‘choose sides.'”

 

Researchers Not ‘Choosing Sides’

Based on their findings, the researchers caution that extra care should be taken when using CRISPR therapeutics. They also propose alternative, less risky, methods, for specific medical procedures, and recommend further research into two kinds of potential solutions: reducing the production of damaged cells or identifying damaged cells and removing them before the material is administered to the patient.

Dr. Barzel and his PhD student Alessio Nahmad conclude: “Our intention in this study was to shed light on potential risks in the use of CRISPR therapeutics. We did this even though we are aware of the technology’s substantial advantages. In fact, in other studies we have developed CRISPR-based treatments, including a promising therapy for AIDS. We have even established two companies – one using CRISPR and the other deliberately avoiding this technology. In other words, we advance this highly effective technology, while at the same time cautioning against its potential dangers. This may seem like a contradiction, but as scientists we are quite proud of our approach, because we believe that this is the very essence of science: we don’t ‘choose sides.’ We examine all aspects of an issue, both positive and negative, and look for answers.”

New Perspectives on Tackling Human Trafficking

Prof. Hila Shamir is among TAU scholars fighting modern slavery.

In light of the World Day against Trafficking in Persons on July 30, we caught up with Prof. Hila Shamir to discuss her trailblazing legal research aimed at combating human trafficking in Israel and around the globe. 

According to the latest estimates, over 40 million people are victims of modern slavery in which individuals perform labor or services under highly exploitative conditions. Their vulnerability to exploitation is often the result of poverty, exclusion or migratory status.  

While trafficking is generally thought of as the exploitation in the sex industry, Shamir is among scholars helping to expand the understanding of the phenomenon to include severe forms of labor market exploitation in other labor sectors. For example, this includes the exploitation of workers in industries such as domestic and care work, construction, agriculture, mining, and fishing who are forced to work in inhumane conditions. Such circumstances include working for long hours, in physically unsafe work environments with little to no pay, and with limitations on their liberties and freedom of movement.  

Top-Down Approach 

“While it is possible to effectively combat human trafficking, to do so requires a willingness to address structural elements, such as restrictive migration regimes and harmful labor market regulation,” says Shamir.  

 

She heads the TraffLab research group at the Buchmann Faculty of Law. Her interdisciplinary team includes students and researchers as well as lawyers from TAU’s Workers’ Rights Clinic, where she serves as the academic advisor. The Clinic supports Shamir’s research through the cases it represents in court. 

Shamir won a competitive grant from the EU’s European Research Council for TraffLab’s research. She was the first legal scholar in Israel to win the ERC Starting Grant for outstanding early-career researchers. The ERC also nominated her lab as a finalist for its 2022 Public Engagement with Research Award for its activity building bridges between research and policymaking. 

Prof. Hila Shamir. (Photo: Hadas Parush/Haaretz)

New Legal Tools 

Shamir’s research seeks to formulate new legal tools to fight human trafficking with labor-based strategies alongside traditional approaches focused on criminal law, border control, and human rights. These strategies target the underlying economic, social and legal structures of labor markets prone to severely exploitative practices.  

With her work, Shamir aims to transform the way trafficking is researched and, as a result, the way anti-trafficking policy is devised. 

While this is no simple feat, she remains optimistic: “There are examples around the world showing us that this can be done if we are willing to move beyond criminalization and expand anti-trafficking toolkit towards strengthening the bargaining power and improving the rights of the most vulnerable workers.”  

She explains that migrant and non-citizen workers are among those most vulnerable to labor trafficking, often due to their legal or social status and institutionalized corruption among employers. 

Impacting the National Debate 

In a significant project, Shamir’s team devised a comprehensive policy plan that proposes alternative recommendations to Israel’s current national plan on trafficking. Shamir recently presented the strategy suggestion to various Israeli government stakeholders and Knesset committees, and held a public roundtable about the plan with the UN Rapporteur on trafficking. The project also led her team to submit several branch-off policy papers over the past year to Israeli policymakers overseeing foreign workers’ rights and related topics. 

Going forward, Shamir is pushing full force ahead with her research as well as public and policy engagement on trafficking. This includes several recent and impending publications based on her research on Israel, modern slavery in global value chains, and bilateral labor agreements, which are among the types of structural frameworks that affect the recruitment practices and labor conditions that can lead to trafficking. 

Historic Designation for TAU’s Cymbalista Synagogue & Jewish Heritage Center

Campus landmark is currently the most modern structure with protected status from top Israeli conservation authority.

The Cymbalista Synagogue and Jewish Heritage Center at Tel Aviv University was designated as a protected “Heritage Site” by one of Israel’s top conservation authorities, TAU announced this week.

Completed in 1998, the building is currently the most-modern from around the country to hold the status from the Council for the Conservation of Heritage Sites in Israel. The designation of this status signifies the building’s unique qualities, both in its architectural and social aspects. The designation ensures the physical preservation of the Cymbalista Synagogue as a building of historic significance.

The Cymbalista Synagogue and Jewish Heritage Center is located at the heart of the campus. With its broad rectangular base rising into two spiraling towers emblematic of a Torah scroll, the impressive building is a landmark work of architecture on campus and in Israel. It functions as a synagogue. The Center also serves as an academic and cultural meeting ground and includes a study room, a library, an auditorium, and a museum. Those affiliated with TAU can use the synagogue as a venue for weddings and bar mitzvahs.

In the Spirit of Respect

Swiss real estate developer, philanthropist, and TAU Honorary Doctor and Governor Norbert Cymbalista and his wife Paulette commissioned the building. It was devised to house a synagogue and bridge the gaps between religious and secular segments of Israeli society—and between the different denominations of Judaism: Orthodox, Conservative and Reform—in an academic environment.

“I am thrilled about the new designation, which reaffirms my decision to create a space in the spirit of respect for tradition, but also in the realization that dialogue and acceptance of different viewpoints are essential for Israel’s development as a democratic society,” says Cymbalista.

 

Cymbalista explains that the building’s initial construction plans were solely for a synagogue. However, the assassination of former Israeli Prime Minister Yitzhak Rabin by an Israeli Jew reinforced Cymbalista’s fear that the most dangerous challenge facing Israel was the rift between the religious and secular segments of the population, which he believed could tear the country apart.

Therefore, he identified the opportunity to do more and create a comprehensive center, where those two realities of Israel life could meet and engage in dialogue within an academic environment. As such, the building’s design was expanded to nearly double the original blueprint to include an auditorium, beit midrash (study facility for Jewish scripture), and Judaica museum—the first of its kind in the Tel Aviv area.

“I hope that the Cymbalista Synagogue and Jewish Heritage Center will continue to serve as a focal point of activity and that I will see its impact on further strengthening ties in my lifetime,” adds Cymbalista.

Symbol of Unity, Community & Pluralism 

“Cymbalista Synagogue and Jewish Heritage Center is situated at the heart of campus and is a symbol and an example of unity and community,” says TAU President Prof. Ariel Porat. “The Center reflects the liberal and pluralistic nature of Tel Aviv University. I would like to express my gratitude to Norbert Cymbalista, a loyal friend of the University and the State of Israel, for his significant contribution to promoting these important values on campus.” 

Renowned Swiss architect Mario Botta designed the building. It contains materials and furnishings from around the world, including the Torah ark made of Pakistani onyx stone, golden-hued stone interior walls from Tuscany, black granite flooring from Zimbabwe, a red brick stone exterior from the Italian Dolomites, and a light wood ceiling from Switzerland.

Dr. Yair Lipshitz, Head of the Cymbalista Jewish Heritage Center at TAU: “The new designation is an immense honor for the Center, and an exciting recognition of its architectural and cultural importance. In many ways, the building is a profound response to the question of what it means to foster Jewish culture at the heart of Tel Aviv University.”

“Its multipurpose functionality offers a complex, dynamic and unique interplay between the various facets of being Jewish in Israel today,” he adds. “The preservation of such a building as a heritage landmark ensures the endurance of the vision that is set in its stones – a vision for a rich, pluralistic, multi-voiced Israeli culture.”

Tel Aviv University Researchers Develop Long Covid Treatment

High-pressure oxygen therapy is now available for millions suffering from long Covid.

A groundbreaking new study from Tel Aviv University, the first of its kind in the world, found a promising treatment for long-term COVID-19 symptoms, based on advanced hyperbaric (high-pressure oxygen) therapy (HBOT).

Long COVID, which affects up to 30% of patients infected by the COVID-19 virus, is characterized by a range of debilitating cognitive symptoms such as inability to concentrate, brain fog, forgetfulness and difficulty recalling words or thoughts – persisting for more than three months, and sometimes up to two years. To date, no effective therapy has been suggested, leaving many millions of sufferers around the world with no remedy.

The researchers: “Our study is the first randomized controlled trial to demonstrate a real solution for long COVID. Patients exposed to an intensive protocol of Hyperbaric Oxygen Therapy treatments showed significant improvement compared to the control group. For millions suffering from long-term COVID-19 symptoms, the study provides new hope for recovery.”

Long Covid – Detrimental to Quality of Life

The study was conducted by the Sagol Center for Hyperbaric Medicine and Research at Tel Aviv University and the Shamir Medical Center (Assaf Harofeh). It was led by Prof. Shai Efrati, Director of the Sagol Center and a faculty member at TAU’s Sackler School of Medicine and Sagol School of Neuroscience, and by Dr. Shani-Itskovich Zilberman from the Sagol Center for Hyperbaric Medicine and TAU’s Sackler School of Medicine. Other chief contributors were Dr. Merav Catalogna, lead data scientist from the Shamir Medical Center (Assaf Harofeh), and Dr. Amir Hadanny from the Sagol Center and TAU’s Sackler School of Medicine. The paper was published in Scientific Reports.

Prof. Efrati explains: “Today, we understand that in some patients, the COVID-19 virus penetrates the brain through the cribriform plate, the part of the skull located just above our nose, and triggers chronic brain injury – mainly in brain regions in the frontal lobe, responsible for cognitive function, mental status and pain interpretation. Consequently, affected patients experience a long-term cognitive decline, with symptoms such as brain fog, loss of concentration and mental fatigue. In addition, since the frontal lobe is damaged, patients may suffer from mood disturbance, depression, and anxiety.”

According to Efrati, these clinical symptoms, identified in patients all over the world, were corroborated by the World Health Organization in an official definition of so-called ‘long COVID’ issued in October 2021, including cognitive dysfunction as one of the common symptoms. A recent study from the Universities of Cambridge and Exeter reported that 78% of long-term COVID-19 patients experienced difficulties with concentration, 69% reported brain fog, and 68% reported forgetfulness. “Thus, long-term COVID-19 effects can be very detrimental to the sufferer’s quality of life,” continues Efrati, “and no effective treatment has yet been found.”

 

Prof. Shai Efrati

 

HBOT – Proven Effective Against other Brain Injuries

“In our study, we harnessed Hyperbaric Oxygen Therapy, already proven effective in the treatment of other forms of brain injury such as stroke, trauma, age-related cognitive decline and treatment-resistant PTSD, to the global effort to find a solution for long COVID-19,” explains Efrati.

 

The study, designed as a prospective, randomized, double-blind, placebo-controlled clinical trial, included 73 patients with reported post-COVID-19 cognitive symptoms such as inability to concentrate, brain fog, forgetfulness and difficulty recalling words or thoughts, persisting for more than three months following an RT-PCR test confirming COVID-19 infection.

Participants were divided into two groups: 37 patients received HBOT treatment, while 36 patients served as a sham-controlled group, receiving placebo treatment. Both patients and investigators were unaware of their designated treatment protocol. The unique protocol consisted of 40 daily HBOT sessions, five sessions per week within a two-month period, in which patients entered a multi-place HBOT chamber and breathed 100% oxygen by mask at 2 atmospheres absolute (ATA) for 90 minutes with oxygen fluctuations. The control group received placebo treatment, breathing normal air. In addition, all participants underwent a computerized cognitive test, as well as advanced high-resolution brain imaging (profusion MRI and DTI) at two points in time – when entering the trial and after its completion.

 

Improved cerebral blood flow by HBOT in patient suffering from post-COVID symptoms (photo:  Sagol Center for Hyperbaric Medicine)

Repairing through Regeneration

The results were highly encouraging: patients treated with HBOT showed significant improvement, while in the control group long COVID symptoms remained largely unchanged.

In HBOT-treated patients, the greatest improvements were exhibited in the global cognitive function, attention, and executive functions (the capacity to plan, organize, initiate, self-monitor and control one’s responses to achieve a goal). Other benefits included better information processing speed, improved psychiatric symptoms, more mental energy, better sleep quality, and less body pain.

All clinical findings were correlated with the participants’ brain images, indicating significant change in the parts of the brain related to each function, which had been visibly damaged by the COVID-19 virus.

Dr. Shani-Itskovich Zilberman: “We know that HBOT repairs brain damage through a process of regeneration – generating new neurons and blood vessels. We believe that the beneficial effects of the unique treatment protocol in this study can be attributed to renewed neuroplasticity and increased brain perfusion in regions associated with cognitive and emotional roles.”

Prof. Efrati: “For the first time, our study proposes an effective treatment for the debilitating long COVID syndrome, repairing brain injury with an intensive protocol of HBOT. Moreover, the study reveals the very real biological damage to brain tissues induced by the COVID-19 virus, and how repairing this damage reduces symptoms and can eventually lead to recovery.”

“From a broader perspective, these findings can also suggest that other neurological and psychiatric syndromes might be triggered by biological agents such as viruses, opening new possibilities for future treatments.” 

Note: For patients with long COVID and other neurological disorders, reliable high-quality HBOT is now available at Aviv Clinics in Florida and Dubai, international arms of the Sagol Center at Shamir Medical Center (Assaf Harofeh) in Israel – administering the same strict protocols, with additional cognitive, physical and nutrition support provided to patients.

Tel Aviv University 1st in Israel According to Taiwan University Rankings for 2022

The international ranking is based on number of publications, citations and research excellence.

The National Taiwan University (NTU) rankings for 2022, published this week, ranks Tel Aviv University first in Israel and 112th in the world. In the ranking for 2021, the University was ranked 144th.

The Hebrew University ranked 273rd, followed by the Technion in 346th place. 

The National Taiwan University ranking is among the top university rankings, along with the Shanghai ranking, the Times ranking, the QS ranking and the US News ranking. The ranking, based entirely on scientific publications, ranks the top 500 universities in the world. As such, it bears resemblance to the Shanghai ranking, which is 60% based on scientific publications (another 30% is for Nobel Prizes and the remaining 10% is used to normalize the score relative to the size of the institution).

The top five universities in the NTU rankings are: Harvard University, Stanford University, John Hopkins University, University of Toronto and the University of Oxford.   

The score of each university consists of the number of publications (25% of the total score), the number of article citations (35%) and research excellence (weighing 40%). Each of these components are measured over a period of 11 years and over the past year or two. The research excellence component includes the so-called “H-Index”, the number of most cited articles and the number of articles in leading journals. 

 

 

Israeli University Rankings 2022 >>

World University Rankings 2022 >> 

4th Covid-19 Vaccine Reduces Risk of Death by 72% Amongst Elderly

Study by Tel Aviv University, Ben Gurion University, and Israeli Ministry of Health included 40K Israelis.

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, found that the fourth COVID-19 vaccine is effective in protecting the elderly from the Omicron variant.

The groundbreaking study included approximately 40,000 elderly Israelis living in institutions supervised by the Ministry of Health’s “Senior Shield” program, a task force launched by Israel’s government to oversee the prevention and control of COVID-19 in the country’s geriatric facilities. According to its results, elderly at-risk individuals vaccinated with the fourth dose of the Pfizer vaccine have a 34% reduced risk of contracting the Omicron variant, a 64-67% reduced risk of requiring hospitalization due to COVID, and a 72% reduced risk of death from the virus.

The study was led by Prof. Khitam Muhsen and Prof. Dani Cohen of the School of Public Health at Tel Aviv University, Prof. Ron Dagan of Ben Gurion University, Prof. Nimrod Maimon, director of the Internal Medicine Department at Soroka Medical Center and until recently head of the Ministry of Health’s Senior Shield program, as well as program staff members Ami Mizrahi, Omri Bodenheimer, and Boris Boltyansky, in collaboration with Lea Gaon and Zafrira Hillel-Diamant of the Ministry’s Department of Geriatrics. The study was published in the prestigious journal JAMA Internal Medicine.

Particularly Vulnerable Population

“Our study compared 24,088 residents of Senior Shield facilities who received a fourth dose of the Pfizer vaccine – that is, the second booster shot – with 19,687 residents who were vaccinated with the first three doses four months or more prior to the follow-up, but who chose not to get the second booster,” explains Prof. Muhsen.

“These are residents of geriatric institutions, nursing homes and assisted living facilities that are part of the Ministry of Health’s Senior Shield system – a total of about 1,000 institutions across the country. This population is particularly vulnerable to infection, morbidity, and mortality from the coronavirus, due to the nature and living conditions of the institutions, the fact that many residents need help with daily activities, and the previous health issues that many of the residents suffer from.”

When the Omicron wave spread throughout Israel between January and March of this year, there was no registered and available vaccine for this variant, which underwent significant mutations in the spike protein that allows the virus to attach to and penetrate human cells. Because the existing COVID-19 vaccines target the spike protein, there has been much discussion in Israel and the rest of the world about the effectiveness of existing vaccines against the Omicron variant in general, and with regards to a second booster shot. Israel was the first country to approve the second booster (the fourth dose of the vaccine) for those aged 60 and above. The present study is based on data from the Senior Shield population database, which constituted the first large group to receive the second booster. Prof. Muhsen points out that this new study was conducted on a national scale, and that it successfully addressed the methodological problems that characterize observational epidemiological studies on the effectiveness of COVID vaccines.

Fourth Dose Saved Many Lives

“We monitored the infections, hospitalizations and mortality rates in these two groups throughout the Omicron wave, and found that the members of the group that received the fourth vaccine were infected at a rate that was 34% less than the control group; were hospitalized for mild-to-moderate illness 64% less, and for severe illness 67% less than the control group; and had a mortality rate that was 72% less than the group vaccinated with only the first three doses,” says Prof. Muhsen.

“These are significant data, because the Senior Shield population is one of the groups who suffer the most severe morbidity from the coronavirus, at a much higher rate than the general population. We assume that the fourth dose of the vaccine boosted the level of neutralizing antibodies, which conferred cross-protection against the Omicron variant. Our study points to the significant benefit of administering the fourth dose of the vaccine and confirms that the policy adopted by the State of Israel was the correct one. The decision to vaccinate at-risk populations with the fourth dose was a wise choice that saved a lot of human lives.”

Prof. Muhsen adds: “This is a groundbreaking and innovative study based on a database of the elderly population in care facilities. Previous studies have been conducted in the general population, and therefore also among relatively young populations with an average age of around 72, whereas the average age in our study was 80. Moreover, in general, people who go to be tested or vaccinated against COVID tend to exhibit positive health behaviors, so it is very difficult to compare their morbidity levels to those of unvaccinated people or those who have been vaccinated with three doses. We have no information as to why some of the residents chose not to receive the fourth vaccine dose, but both groups in our study underwent routine and ‘blind’ COVID tests according to uniform Senior Shield protocol, regardless of whether they received the vaccine. Therefore, our study was less affected by the ‘healthy vaccinee effect,’ and its results can also be applied to other populations, in Israel and around the world.”

According to Prof. Dani Cohen, “The study indicates that giving booster shots and raising the level of antibodies through a vaccine based on the original COVID-19 strain provides significant protection against the onset of serious illness even after infection with new variants, including those that are very different from the original, such as Omicron.”

Prof. Nimrod Maimon adds that “The task of protecting institutions for people living outside of the home is a very important aspect of the Ministry of Health’s Senior Shield program. The database that the project has built and accumulated about the institutions and their residents has allowed for rapid and effective vaccination campaigns, which have yielded dramatic results in curbing illness from the coronavirus amongst these populations. The impressive results of the program have received widespread international praise, with health authorities from many countries around the world seeking to learn from the Senior Shield program.”

Prof. Ron Dagan concludes that the results presented in the study demonstrate once again the critical role of vaccines and the use of structured and effective systems in curbing waves of severe morbidity and mortality in at-risk populations.

Going to the Beach? Sun Exposure Makes Men Hungrier than Women

TAU researchers find surprising connection between sun exposure and men’s appetite.

A new study from Tel Aviv University reveals that solar exposure increases appetite in males, but not in females. It is the first gender-dependent medical study ever conducted on UV exposure, and for the first time, the molecular connection between UV exposure and appetite was deciphered.

Skin as Regulator of Appetite

The groundbreaking study was led by Prof. Carmit Levy and PhD student Shivang Parikh of the Department of Human Molecular Genetics and Biochemistry at TAU’s Sackler Faculty of Medicine. It was conducted in collaboration with many researchers in Israel and worldwide, including contributors from Tel Aviv Sourasky (Ichilov), Assuta, Meir, and Sheba Medical Centers, along with Dr. Yiftach Gepner and Dr. Lior Bikovski from TAU’s Sackler Faculty of Medicine, and Prof. Aron Weller of Bar-Ilan University. The paper was published in the prestigious journal Nature Metabolism.

The study was based on epidemiological data collected in a year-long survey about the eating habits of approximately 3,000 Israelis of both sexes, including self-reports from students who had spent time in the sun, combined with the results of a genetic study in a lab model. The findings identify the skin as a primary regulator of energy and appetite (metabolism) in both lab models and humans.

 

Prof. Carmit Levy

Estrogen Hormone Blocks Urge to Eat in Women

The study unravels the differences between males and females in the activation of the metabolic mechanism. The researchers explain that in males of both animal species and humans, sun exposure activates a protein called p53, to repair any DNA damage in the skin that might have been caused by the exposure. The activation of p53 signals the body to produce a hormone called ghrelin, which stimulates the appetite.

In females, the hormone estrogen blocks the interaction between p53 and ghrelin, and consequently does not catalyze the urge to eat following exposure to the sun.

The researchers explain that there is a dramatic metabolic difference between males and females, impacting both their health and their behavior. However, so far it has not been established whether the two sexes respond differently to environmental triggers such as exposures to the sun’s UV radiation.

“We examined the differences between men and women after sun exposure and found that men eat more than women because their appetite has increased. Our study was the first gender-dependent medical study ever conducted on UV exposure, and for the first time, the molecular connection between UV exposure and appetite was deciphered. Gender-dependent medical studies are particularly complex, since twice the number of participants is required to find statistically significant differences,” explains Prof. Levy.

“As humans, we have cast off our fur and consequently, our skin, the largest organ in our body, is exposed to signals from the environment. The protein p53, found in the skin, repairs damage to the DNA caused by sun exposure, but it does more than that. It signals to our bodies that winter is over, and we are out in the sun, possibly in preparation for the mating season. Our results provide an encouraging basis for more research, on both human metabolism and potential UV-based therapies for metabolic diseases and appetite disorders,” Prof. Levy concludes.

Impressive achievement for Tel Aviv University in the Bar Association Exam

100% of the TAU alumni who took the Bar Association exams for the first time, passed successfully and Tel Aviv University also leads with the highest average grade.

For the first time, 100% of the TAU examinees who took their Bar Association exams for the first time, passed it successfully, according to the Israel Bar Association.

Tel Aviv University also leads with the highest average grade and overall passing rate (including those who did not take the exam for the first time) of 94%. 

“Israel’s Future Legal Leaders”

The impressive achievement of a 100% passing rate among alumni taking the exam for the first time was also recorded at Bar-Ilan and Haifra universities. In fourth place among those taking the exam for the first time is the Hebrew University (95%). According to the Israel Bar Association, this is a first time increase in the percentage of examinees passing. 

There were a total of 1,506 examinees in the end of June, and 47% of them passed. The percentage of examinees passing the exams on first attempt (597 individuals) is significantly higher than the general passing rate, and stands at 64%.

Like last year, there is a gap between the percentage of passing grades between university and college graduates (although the gaps have narrowed), 87% of the university alumni passed the exam and 41% of the college graduates. 

An analysis of the data by place of specialization, shows that the military/police prosecutor’s office achieved the highest percentage of passing the exam, with 76%; in second place is the state prosecutor’s office for its districts with 65%. Most of the examinees come from the private sector, where the passing rate is 39% out of 1,163 examinees. 

Prof. Yishai Blank, Buchmann Faculty of Law Dean, says, “I am especially proud that the alumni of TAU’s Faculty of Law have, once again, achieved top Bar Examination results with 100% passing the exam and overall earning the highest scores in the country. We are proud of them and the excellent legal training that the Faculty provides them during their studies, preparing them to become Israel’s future legal leaders.” 

While You Were Sleeping

Could we be one step closer to verifying whether a seemingly unconscious person is truly unaware of his or her surroundings?

A new TAU discovery may provide a key to a great scientific enigma: How does the awake brain transform sensory input into a conscious experience? The researchers were surprised to discover that the brain’s response to sound remains powerful during sleep in all parameters but one: the level of alpha-beta waves associated with attention to the auditory input and related expectations. This means that during sleep, the brain analyzes the auditory input but is unable to focus on the sound or identify it, and therefore no conscious awareness ensues.

The study was led by Dr. Hanna Hayat and with major contribution from Dr. Amit Marmelshtein, at the lab of Prof. Yuval Nir from the School of Medicine of the Sackler Faculty of Medicine, the Sagol School of Neuroscience, and the Department of Biomedical Engineering, and co-supervised by Prof. Itzhak Fried from the UCLA Medical Center. Other participants included: Dr. Aaron Krom and Dr. Yaniv Sela from Prof. Nir’s group, and Dr. Ido Strauss and Dr. Firas Fahoum from the Tel Aviv Sourasky Medical Center (Ichilov). The paper was published in the prestigious journal Nature Neuroscience.

A Deep Dive into the Human Brain

Prof. Nir explains that this study is unique in that it builds upon rare data from electrodes implanted deep inside the human brain, enabling high-resolution monitoring, down to the level of individual neurons, of the brain’s electrical activity.

While electrodes cannot be implanted in the brain of living humans just for the sake of scientific research, in this case the researchers were able to utilize a special medical procedure in which electrodes were implanted in the brains of epilepsy patients, monitoring activity in different parts of their brain for purposes of diagnosis and treatment. The patients volunteered to help examine the brain’s response to auditory stimulation in wakefulness versus sleep.

The researchers placed speakers emitting various sounds at the patients’ bedside and compared data from the implanted electrodes – neural activity and electrical waves in different areas of the brain – during wakefulness and during various stages of sleep. Altogether, the team collected data from over 700 neurons (about 50 neurons in each patient) over the course of 8 years.

 

Dr. Hanna Hayat

Measuring the Strength of Alpha-beta Waves

“After sounds are received in the ear, the signals are relayed from one station to the next within the brain,” explains Dr. Hayat. “Until recently it was believed that during sleep these signals decay rapidly once they reach the cerebral cortex.  But looking at the data from the electrodes, we were surprised to discover that the brain’s response during sleep was much stronger and richer than we had expected. Moreover, this powerful response spread to many regions of the cerebral cortex. The strength of brain response during sleep was similar to the response observed during wakefulness, in all but one specific feature: the level of activity of alpha-beta waves.”

The researchers explain that alpha-beta waves (10-30Hz) are linked to processes of attention and expectation that are controlled by feedback from higher regions in the brain. As signals travel ‘bottom-up’ from the sensory organs to higher regions, a ‘top-down’ motion also occurs: the higher regions, relying on prior information that had accumulated in the brain, act as a guide, sending down signals to instruct the sensory regions as to which input to focus on, which should be ignored, etc. Thus, for example, when a certain sound is received in the ear, the higher regions can tell whether it is new or familiar, and whether it deserves attention or not.

“We hope that our findings will serve as a basis for developing effective new methods for measuring the level of awareness of individuals who are supposedly in various states of unconsciousness.”

This kind of brain activity is manifested in the suppression of alpha-beta waves, and indeed, previous studies have shown a high level of these waves in states of rest and anesthesia. According to the current study, the strength of alpha-beta waves is the main difference between the brain’s response to auditory inputs in states of wakefulness vs. sleep.

Decoding Consciousness

Prof Nir summarizes: “Our findings have wide implications beyond this specific experiment. First, they provide an important key to an ancient, fascinating enigma: What is the secret of consciousness? What is the ‘X-factor’, the brain activity that is unique to consciousness, allowing us to be aware of things happening around us when we are awake, and disappearing when we sleep? In this study we discovered a new lead, and in future research we intend to further explore the mechanisms responsible for this difference. 

“In addition, having identified a specific brain feature that is different between states of consciousness and unconsciousness, we now have a distinct quantitative measure – the first of its kind – for assessing an individual’s awareness of incoming sounds. We hope that in the future, with improved techniques for measuring alpha-beta brain waves, and non-invasive monitoring methods such as EEG, it will be possible to accurately assess a person’s state of consciousness in various situations: verifying that patients remain unconscious throughout a surgical procedure, monitoring the awareness of people with dementia, or determining whether an allegedly comatose individual, unable to communicate, is truly unaware of his/her surroundings. In such cases, low levels of alpha-beta waves in response to sound could suggest that a person considered unconscious may in fact perceive and understand the words being said around him. We hope that our findings will serve as a basis for developing effective new methods for measuring the level of awareness of individuals who are supposedly in various states of unconsciousness. “

 

Victoria

Tok Corporate Centre, Level 1,
459 Toorak Road, Toorak VIC 3142
Phone: +61 3 9296 2065
Email: [email protected]

New South Wales

Level 22, Westfield Tower 2, 101 Grafton Street, Bondi Junction NSW 2022
Phone: +61 418 465 556
Email: [email protected]

Western Australia

P O Box 36, Claremont,
WA  6010
Phone: :+61 411 223 550
Email: [email protected]